rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HUMA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      StoneX reiterates Humacyte stock rating on strong sales growth
      Nov 12Investing.comHUMA
      Humacyte, Inc. Q3 2026 Earnings Call Summary
      Nov 10Yahoo FinanceHUMA
      Humacyte Q3 Earnings Call Highlights
      Nov 10Yahoo FinanceHUMA
      Earnings call transcript: Humacyte beats Q3 2026 estimates as Symvess sales jump
      Nov 10Investing.comHUMA
      Humacyte Q3 2026 Earnings Call Transcript
      Nov 10BenzingaHUMA
      Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates
      Nov 10Yahoo FinanceHUMA
      Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

      The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.4, representing a -12.11% change from its previous close.

      Nov 5Yahoo FinanceHUMA
      Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

      Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.

      Oct 30Yahoo FinanceHUMA
      Humacyte receives U.S. patent for Symvess manufacturing process
      Oct 28Investing.comHUMA
      Humacyte reports positive trial results for dialysis access device
      Oct 23Investing.comHUMA
      Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

      Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.

      Oct 21Yahoo FinanceHUMA
      Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

      In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.

      Oct 19Yahoo FinanceHUMA
      Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Healthequity (HQY)

      Detailed price information for Humacyte Inc (HUMA-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailHQYHUMA
      Humacyte stock price target reiterated at $1 by StoneX on demand
      Oct 16Investing.comHUMASNEX
      Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy
      Oct 16Investing.comHUMA
      Humacyte reports 44% jump in hospitals ordering Symvess in Q3
      Oct 15Investing.comHUMA
      Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
      Oct 13Yahoo FinanceHUMA
      Humacyte’s phase 3 dialysis access trial results to be presented
      Oct 12Investing.comHUMA
      Humacyte to Present Phase 3 Dialysis Access Trial Results at ASN Kidney Week
      Oct 12Yahoo FinanceHUMA
      Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts
      Oct 9Yahoo FinanceHUMA
      Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

      Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.

      Oct 6Yahoo FinanceHUMA
      Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
      Oct 1Yahoo FinanceHUMA
      Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

      DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...

      Sep 28Business InsiderHUMA
      Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

      Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.

      Sep 18Yahoo FinanceHUMA
      Humacyte at H.C. Wainwright conference: dialysis push takes center stage
      Sep 16Investing.comHUMA
      Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b

      Sep 10Yahoo FinanceHUMA
      Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

      – FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a

      Sep 9Yahoo FinanceHUMA
      Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months

      Humacyte (HUMA) said Wednesday the US Food and Drug Administration has authorized an extension of th

      Sep 9Yahoo FinanceHUMA
      Humacyte plans November FDA filing for dialysis access use
      Aug 24Investing.comHUMA
      Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

      – Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis access study found that women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – DU

      Aug 24Yahoo FinanceHUMA
      Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

      Humacyte (HUMA) said Monday it plans to file in November a supplemental biologics license applicatio

      Aug 24Yahoo FinanceHUMA
      Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
      Aug 22MorningstarHUMA

      This is the newest page. Registered accounts read further back.